FMP
NASDAQ
18.24 USD
0.28 (1.54%)
Dr. Kevin Koch Ph.D.
Healthcare
Biotechnology
https://www.edgewisetx.com
NASDAQ
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
0001710072
US28036F1057
28036F105
3415 Colorado Avenue
303 735 8373
US
88
Mar 26, 2021
0001710072
NASDAQ
Biotechnology
Healthcare
28036F105
US28036F1057
US
18.24
0.12
1.04M
1.7B
-
5.12-20.69
1.27
-
-
-
-
-11.62
-
https://www.edgewisetx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.